Key result
Insulin-treated diabetic patients with NSTE ACS were less likely than nondiabetics to receive aspirin (OR 0.83; 95% CI 0.74-0.93) and had higher in-hospital mortality (6.8% vs 4.4%).
Why the study?
Does diabetes status affect adherence to guideline-recommended therapies and outcomes in patients presenting with NSTE ACS?
Observational (n=46,410)
Yes
Does diabetes status affect adherence to guideline-recommended therapies and outcomes in patients presenting with NSTE ACS?
Effect estimate: adjusted OR 0.83 (95% CI 0.74-0.93)
Patients with insulin-treated diabetes presenting with NSTE ACS receive guideline-recommended medical and invasive therapies less frequently than nondiabetic patients, despite experiencing higher in-hospital mortality.
No takes yet. Share an insight, caveat, or question.
May signal care gaps for insulin-treated diabetes in NSTE ACS; hypothesis-generating for targeted interventions.
Brogan et al. (2006) conducted an observational in non-ST-segment elevation acute coronary syndromes (n=46,410). Insulin-treated diabetes vs. Nondiabetic patients was evaluated on Receipt of aspirin (adjusted OR 0.83, 95% CI 0.74-0.93). Insulin-treated diabetic patients with NSTE ACS were less likely than nondiabetics to receive aspirin (OR 0.83; 95% CI 0.74-0.93) and had higher in-hospital mortality (6.8% vs 4.4%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: